Use of Human Embryonic Stem Cells in the Treatment of Diabetes Mellitus: A Case Series
- 1 Nutech Mediworld, New Delhi, India
Abstract
Introduction: Diabetes mellitus (DM), a metabolic disorder, is known to be highly prevalent in people aged 40 - 60 years in developing countries whereas in developed countries, it mostly affects people above the age of 60 years. It is of two types: DM type I, an autoimmune disorder that mostly onsets after an infection and DM type II that is commonly associated with obesity. Several treatments are available for the treatment of DM, but none has successfully cured diabetes. Nowa days, stem cell therapy is being investigated for use in the treatment of DM and has shown positive results. Case Report: Our study presented results of three diabetic patients who were treated with human embryonic stem cell (hESC) therapy. Following the therapy, blood glucose levels were reduced. An improvement was observed in eye sight, stamina, gait pattern endurance, mental focus ability and muscle strength. There was a reduction in secondary side effects of high blood sugar such as affectation of cardiac, kidneys, polyneuropathy, vision etc. No adverse events and tera toma formation were observed after the treatment. Conclusion: It was concluded that hESCs showed good therapeutic potential in the treatment of patients with diabetes.
- Shaw, J.E., Sicree, R.A. and Zimmet, P.Z. (2010) Global Estimates of the Prevalence of Diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 87, 4-14. http://dx.doi.org/10.1016/j.diabres.2009.10.007
- American Diabetes Association (2013) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 36, S67-S74.
- National Diabetes Information Clearinghouse (NDIC) http://diabetes.niddk.nih.gov/dm/pubs/causes/
- Harris, M.I. (2004) Definition and Classification of Diabetes Mellitus and the Criteria for Diagnosis. In: LeRoith, D., Taylor, S.I. and Olefsky, J.M., Eds., Diabetes Mellitus: A Fundamental and Clinical Text, 3rd Edition, Lippincott Williams & Wilkins, Philadelphia, 457-467.
- Forbes, J.M. and Cooper, M.E. (2013) Mechanisms of Diabetic Complications. Physiological Reviews, 93, 137-188. http://dx.doi.org/10.1152/physrev.00045.2011
- Hofmann, S. and Brownlee, M. (2004) Biochemistry and Molecular Cell Biology of Diabetic Complications: A Unifying Mechanism. In: LeRoith, D., Taylor, S.I. and Olefsky, J.M., Eds., Diabetes Mellitus: A Fundamental and Clinical Text, 3rd Edition, Lippincott Williams & Wilkins, Philadelphia, 1441-1456.
- Davey, G.C., Patil, S.B., O’Loughlin, A. and O’Brien, T. (2014) Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus. Frontiers in Endocrinology (Lausanne), 5, 86.
- Asghar, O., Al-Sunni, A., Khavandi, K., et al. (2009) Diabetic Cardiomyopathy. Clinical Science (London), 116, 741-760. http://dx.doi.org/10.1042/CS20080500
- Falanga, V. (2005) Wound Healing and Its Impairment in the Diabetic Foot. The Lancet, 366, 1736-1743. http://dx.doi.org/10.1016/S0140-6736(05)67700-8
- Zintzaras, E., Miligkos, M., Ziakas, P., et al. (2014) Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis. Clinical Therapeutics, 36, 1443-1453. http://dx.doi.org/10.1016/j.clinthera.2014.06.035
- Trujillo, J.M. and Nuffer, W. (2014) GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents. Pharmacotherapy, 34, 1174-1186. http://dx.doi.org/10.1002/phar.1507
- Aathira, R. and Jain, V. (2014) Advances in Management of Type 1 Diabetes Mellitus. World Journal of Diabetes, 5, 689-696. http://dx.doi.org/10.4239/wjd.v5.i5.689
- Shroff, G., Gupta, A. and Barthakur, J. (2014) Therapeutic Potential of Human Embryonic Stem Cell Transplantation in Patients with Cerebral Palsy. Journal of Translational Medicine, 12, 318. http://dx.doi.org/10.1186/s12967-014-0318-7